Cardiogen: heart-tissue peptide studied in aging research
A short synthetic peptide that stimulated heart-muscle cell growth in aged rat tissue experiments; experimental, not an approved drug.
- Class
- Khavinson bioregulator short peptide (myocardial)
- Status
- No approved therapeutic status. Research chemical (Western markets) or oral dietary peptide complex (Russian market). Not approved by FDA, EMA, MHRA, Health Canada, or TGA.
- Best-supported effect
- Stimulation of cell proliferation in aged-rat myocardial tissue explants (organotypic tissue-culture model); no human efficacy data identified in this card's source.
- Main caveat
- All published Cardiogen-specific evidence is from rodent and ex vivo tissue-culture systems; no human clinical trials are indexed; independent Western replication is essentially absent; vendor and forum claims around cardiac regeneration in humans substantially exceed what the evidence base supports.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Khavinson bioregulator short peptide (myocardial)
Evidence tier: Animal-only evidence
Status: No approved therapeutic status. Sold as a research chemical (Western markets) or oral dietary peptide complex (Russian market). Not approved by FDA, EMA, MHRA, Health Canada, or TGA.
Best-supported effect: Stimulation of cell proliferation in aged-rat myocardial tissue explants (organotypic tissue-culture model); no human efficacy data identified in available literature.
Main caveat: All published Cardiogen-specific evidence is from rodent and ex vivo tissue-culture systems; no human clinical trials are indexed; independent Western replication is essentially absent; vendor and forum claims around cardiac regeneration in humans substantially exceed what the evidence base supports.
What this is
Cardiogen is a synthetic short peptide bioregulator from the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology, identified in available literature as the tripeptide Ala-Glu-Asp (AED). It occupies the myocardial slot in a catalog of organ-targeted short peptides that includes analogues for vasculature (Vesugen / KED), liver (Livagen / KEDA), and cortex (Cortagen / AEDP). The Khavinson program's design rationale holds that short peptides with tissue-specific sequences can selectively interact with the relevant organ's cells and modulate age-altered gene expression. Cardiogen is the heart-tissue counterpart in that framework, with proposed applications in age-related cardiac function decline, post-infarct recovery, and cardiomyocyte support. The sequence attribution (AED) comes primarily from Khavinson-aligned sources and commercial product listings; a definitive published structural paper confirming the sequence is not reported in the available literature, and published literature explicitly notes this as a caveat on the peptide's identity.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | None identified | No human clinical trial data identified in available literature. Russian-language clinical observations are mentioned in available literature but none meet controlled-trial standards and are not individually extracted here. |
| Animal | Weak | Organotypic tissue-culture study in young vs. old rats showing age-dependent proliferative stimulation in myocardial explants; tumor-modifying effects on M-1 sarcoma in senescent rats. Both studies are from the Khavinson research network; no independent Western preclinical replication identified. |
| In vitro | Weak | The organotypic tissue-culture model (rat myocardial explants) overlaps with in vitro methodology; findings limited to cell-proliferation endpoints in tissue explants. |
| Computational | None identified | No computational or structural-prediction data identified. |
| Mechanism | Proposed, not independently validated | Source proposes direct DNA-regulatory-region and histone interaction in cardiomyocytes, with chromatin accessibility modulation and reactivation of silenced gene programs in aged myocardium. This framework is not independently validated; structural characterization of proposed DNA binding, identification of regulated gene sets in cardiomyocytes, and receptor or binding-partner data are absent. The broader Khavinson tissue-specificity mechanism has some ex vivo chromatin-decondensation support for Livagen in human lymphocytes, but Cardiogen-specific mechanistic data are essentially absent. |
A large share of the published Cardiogen-specific evidence comes from the Khavinson research network; independent replication by Western cardiology or structural-biology laboratories has not been identified in the available literature.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Stimulates cell proliferation in aged myocardial tissue ex vivo | Supported (animal / ex vivo) | Animal / in vitro | Low — single Khavinson-network study, organotypic tissue-culture model only, no independent replication |
| Age-related cardiac function decline support | Weak (preclinical) | Animal | Low — source inference from tissue-culture proliferation data; no functional cardiac-output or in vivo cardiac-performance endpoints reported |
| Post-infarct recovery support | Not established | None | High confidence in verdict — no infarct-model animal study or human evidence identified in available literature |
| Cardiac regeneration or heart-muscle repair in humans | Not established | None | High confidence in verdict — vendor and community claims substantially exceed the available evidence base |
| Tissue-specific gene-expression modulation in cardiomyocytes | Weak (preclinical, mechanistic inference) | Animal | Low — proposed framework consistent with other Khavinson peptides; no structural, transcriptomic, or target-binding validation specific to Cardiogen |
Experimental exposure
This section reports exposure conditions used in the animal and ex vivo studies identified in available literature. It does not establish animal in vivo dosing or human exposure.
| Context | System | Experimental exposure | Duration / timepoint | Endpoint | Limitation |
|---|---|---|---|---|---|
| Organotypic tissue-culture study [R2] | Myocardial explants from young and old rats | Source-described peptide application; exact concentration not individually extracted | Study-defined timepoints | Cell proliferation in tissue explants (age-dependent response) | Ex vivo model; no in vivo pharmacokinetics; no translation to systemic exposure established |
| Senescent-rat tumor-modifying study [R1] | Senescent rats bearing M-1 sarcoma | Source-described dose; exact dose not individually extracted | Study-defined course | Tumor growth dynamics in aged animals | Off-target tumor model; mechanism and direction of effect difficult to interpret therapeutically; not a cardiac-function study |
Preclinical safety signals
| Signal | System | Notes |
|---|---|---|
| No significant adverse effects reported | Rodent / ex vivo tissue-culture studies | Per available sources, general tolerability in the small published literature; no detailed toxicology extracted |
| Tumor-modifying effects in senescent rats | Senescent-rat M-1 sarcoma model | Source describes modulation of M-1 sarcoma growth dynamics [R1]; direction and mechanism are context-sensitive; source notes this argues for caution rather than a straightforward therapeutic claim |
| Theoretical proliferative or arrhythmogenic risk in diseased myocardium | Preclinical / theoretical | Source raises concern about unintended proliferative or arrhythmogenic effects in diseased myocardium; not addressed in animal infarct models or in humans |
| Long-term safety | Not established | No formal human safety studies, no human pharmacokinetics, no long-term safety data identified in source |
| Interactions with cardiovascular pharmacotherapy | Unknown | Source notes interactions with standard cardiovascular pharmacotherapy are uncharacterized |
| Quality and purity of research-chemical supply | Not established | Source notes quality, purity, and identity cannot be assumed from research-chemical supply; injection-site reactions possible with supply of uncertain sterility |
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved | Not approved for any indication; not recognized as a dietary supplement ingredient; not listed among peptides eligible for 503A compounding per the available literature; research-chemical injectable form sold as "not for human use" |
| EU (EMA) | Not approved | Not approved as a medicine per the available literature |
| UK (MHRA) | Not approved | Not approved per the available literature |
| Canada (Health Canada) | Not approved | Not approved per the available literature |
| Australia (TGA) | Not approved | Not approved per the available literature |
| Russia / Russian market | Sold as oral dietary peptide complex | Available under Peptides.ru / Khavinson Peptides brand as a functional food rather than a registered prescription medicine; not a Western-standard drug approval |
| WADA | per available sources as likely prohibited under S0 | Per available sources, Cardiogen is not specifically named on the WADA Prohibited List but states injectable Cardiogen reasonably falls under the WADA S0 catch-all category for substances not currently approved by any governmental regulatory health authority for human therapeutic use; current WADA list status not independently verified in this card |
Mechanism
Within the Khavinson bioregulator framework, Cardiogen (proposed sequence Ala-Glu-Asp) is proposed to act through direct interaction with DNA regulatory regions and histone proteins in cardiomyocytes, modulating chromatin accessibility and reactivating gene expression programs that become progressively silenced in aging heart tissue. The broader tissue-specificity claim across the Khavinson catalog holds that each short peptide preferentially activates cells of its named target tissue through sequence-specific DNA recognition.
The Cardiogen-specific mechanistic evidence is essentially absent: no structural characterization of proposed DNA binding, no identification of regulated gene sets in cardiomyocytes, and no receptor or binding-partner data have been reported. a concrete molecular mechanism for how a tripeptide achieves tissue-specific gene regulation has not been established even within the Khavinson literature, and has not been independently validated by Western structural biology or chromatin research. The main observation — age-dependent stimulation of cell proliferation in myocardial explants — is interpreted by the Khavinson group as evidence of reactivation of silenced gene programs [R2], but the mechanistic chain is inferred rather than demonstrated.
Chemistry
| Field | Value |
|---|---|
| Proposed sequence | Ala-Glu-Asp (AED) |
| Length | 3 amino acids (tripeptide) |
| Topology | Linear |
| Modifications | None described in source |
| Molecular weight | Not extracted from source |
| Formula | Not extracted from source |
| CAS | Not extracted from source |
| Sequence confidence | Needs review — published literature explicitly notes reliable confirmation of the exact amino acid sequence in peer-reviewed literature is limited; the AED attribution comes primarily from Khavinson-aligned sources and commercial product listings, not from a definitive published structural paper |
Open questions
- Human evidence: No controlled human trial of Cardiogen for any cardiovascular or aging indication has been identified in available literature. Whether the ex vivo proliferation effects in aged-rat myocardial tissue translate to human cardiac function is entirely unknown and represents the primary gap before any human-efficacy claim can be assessed.
- Sequence confirmation: The AED tripeptide attribution is per available sources from Khavinson-aligned publications and commercial listings. A definitive peer-reviewed structural paper confirming the sequence is absent from the available literature. Until sequence identity is confirmed by an independent source, all chemistry and mechanistic claims carry elevated uncertainty.
- Mechanistic validation: The proposed direct-DNA-interaction and chromatin-modulation mechanism has not been characterized structurally or molecularly for Cardiogen specifically. What gene targets are regulated in cardiomyocytes, what binding affinity exists, and how a tripeptide achieves claimed tissue specificity remain unestablished.
- Safety in diseased myocardium: Source raises theoretical concern about unintended proliferative or arrhythmogenic effects in diseased myocardium. This has not been addressed in animal infarct models, let alone in humans with structural heart disease.
- Independent replication: The published Cardiogen evidence is concentrated in the Khavinson research network. Independent Western preclinical replication in cardiology or structural-biology laboratories has not been identified in the available literature.
- Oral bioavailability: Russian-market oral capsule products represent one distribution channel, but published research does not report oral bioavailability or pharmacokinetic data for an oral tripeptide route of administration.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Would swapping the last amino acid of AEDR to its mirror-image version help the peptide survive inside heart cells long enough to reach the nucleus where genes are controlled?
Many short peptides are destroyed inside cells before they can reach their target. A single chemical swap that makes Cardiogen survive inside heart muscle cells could dramatically improve its effectiveness at reactivating genes involved in heart repair and maintenance in older patients.
▸3-letter notation
▸citationbibtex
@peptide{pep10939,
sequence = {AEDR},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}